This research addresses a critical question for stroke survivors and their families. Many people with acute ischaemic stroke suffer from blockages in medium or distal blood vessels. These patients often present at hospitals within six hours of their last known well time. For years, doctors have debated whether adding endovascular treatment to standard medical care helps these specific patients. This study aimed to answer that question directly. The results suggest that for mild-to-moderate cases, the extra procedure may not be necessary. Understanding this finding helps patients avoid unnecessary risks and invasive procedures. It also guides doctors on when to recommend surgery versus standard medication.
The study involved 553 adults enrolled across 55 hospitals in Europe and the Middle East. Participants were adults aged 18 years or older with acute ischaemic stroke. The blockage had to be in a medium or distal vessel. Patients came from home within six hours of their last known well time. Some were seen between six and 24 hours if imaging showed salvageable brain tissue. All participants received best medical treatment. The intervention group also received endovascular treatment. The control group received best medical treatment alone.
Researchers measured disability at 12 months using the ordinal modified Rankin Scale. Scores of 5 and 6 combined indicate severe disability or death. The median score was 2 in both groups. This score falls within the range of mild disability. The study found no difference in disability between the two groups. The adjusted common odds ratio was 0.81. The 95% confidence interval ranged from 0.59 to 1.12. The p-value was 0.20. This indicates no statistically significant reduction of disability with the added treatment. Overall survival was also similar between groups. The hazard ratio was 1.46 with a p-value of 0.10. No serious adverse events were reported during the study period.
The study had an open-label design. This means the doctors and patients knew which treatment was given. This can sometimes influence results. Funding came from the Swiss National Science Foundation and several medical device companies. These include Medtronic, Stryker Neurovascular, and others. Because the study was open-label and funded by industry, readers should interpret the results with caution. The sample size of 553 patients is moderate but may not represent every possible scenario. The findings apply specifically to medium or distal vessel occlusions. They do not apply to large vessel occlusions or other stroke types.
Routine endovascular treatment is therefore not supported for patients with mild-to-moderate medium or distal vessel occlusion stroke. Patients should discuss these findings with their doctors. Doctors should not overstate the importance of this single study. It does not prove that endovascular treatment is useless for all strokes. It only shows no benefit for this specific group. Patients should not stop prescribed treatments without medical advice. This study helps clarify when invasive procedures are truly needed. It supports a more conservative approach for certain stroke patients. The goal is to provide care that matches the patient's specific condition without unnecessary risk.
